* BIOALLIANCE PHARMA *
1997 - IDF
Paris
www.bioalliancepharma.com Discovery, Drugs
(also Delivery, Drugs)
Key words: Cancer, HIV, Opportunistic infections
Mission: to discover, develop and market innovative treatments rapidly evolving therapeutic markets -cancer, serious viral diseases (such as HIV) and opportunistic infections- with NCE's ans drug delivery improvements
Clients: Prescribers
bioalliance@bioalliancepharma.com
Age: 13 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Costantini (Dominique) [co-founder, born 1955, M.D., ex-Hoechst-Marion-Roussel]
Oper.Dir.: Avenard (Gilles) [co-founder, born 1951, M.D., ex-Hoechst-Marion-Roussel, CNTS]
Sc.Dir.-CSO: Auclair (Christian) [Pharm.D., Ph.D., University Prof.]
Fin.Dir.-CFO: Fellman (Nicolas) [MBA, ex-Pfizer, Ernst & Young]
SalesMktg: Dupré (Florence)
BusDev:
Financers (Hist.): 3i, Auriga Partners, ING, Capricorn Venture, ABN-AMRO, SPEF Ventures, AGF P.E., Public | Turnover (M€) : 1.1 (2008), 3.5 (2007)
Total funding (M€) : 91.0
Last funding (M€) : 40.0
Focus : Cancers
Position : Launch
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2009 .12 | Clinical trial (phase II) for Clonidine Lauriad (beginning) in radiotherapy and chemotherapy-induced oral mucositis and clinical trial (phase I) for AMEP (beginning) in invasive melanoma | CLIN | [12 years] |
| 2009 .10 | Clinical trial (phase I) for Fentanyl Lauriad, slow-release central analgesic in cancer patients (beginning) | CLIN | [12 years] |
| 2009 .04 | Clinical trial planned, after first preclinical trial results on new oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer | CLIN | [12 years] |
| 2009 .04 | Financing (no interest loan) : 6.3 M€, by OSEO Innovation, to support Cancer Anti-invasive Program (CAP) private-public consortium (with Oroxcell and Xentech) | DEBT | [12 years] |
| 2009 .03 | Licensing-out of Loramyc rights to SpeBio (2007) in Europe regained (withdrawn contract and legal suite) | LICOUT | [12 years] |
| 2009 .02 | Registration : submission to EMEA of ondansetron RapidFilm | MKTG | [11 years] |
| 2008 .12 | Management restructuring : 9 heads employee reduction, i.e. 12% of total headcounts | ORGR | [11 years] |
| 2008 .09 | Financing : capital investment by AGF Private Equity (over 5% of equity) | RFIN | [11 years] |
| 2008 .08 | Nomination : Pierre Morgon as COO, along Gilles Avenard (Pierre Morgon resigns in May 2009) | ORGN | [11 years] |
| 2008 .05 | Licensing-in of European rights of Ondansetron spray from NovaDel | LICIN | [11 years] |
| 2008 .03 | Company (as Laboratory BioAlliance Pharma) founded by Dominique Costantini for Marketing and Trade | ORGF | [11 years] |
| 2007 .09 | Launch of Loramyc on French market | MKTG | [10 years] |
| 2007 .07 | 4th round-financing : 40.0 M€, led by Bryan, Garnier & Co, with international investors (private capital increase) | RFIND | [10 years] |
| 2007 .03 | Licensing-out of Loramyc to PAR pharmaceuticals in USA, in a deal valued 95 MUS$ (15 MUS$ initially, plus milestones) | LICOUT | [10 years] |
| 2006 .10 | Registration : obtained for Loramyc, in France | MKTG | [9 years] |
| 2005 .12 | Public offering : 30.0 M€, Alternext, Eurolist | PBO | [8 years] |
| 2004 .08 | 3rd round-financing : 2.0 M€ (follow-up), by Siparex Ventures | RFINC | [7 years] |
| 2003 .05 | 3rd round-financing : 10.0 M€, led by Auriga Partners | RFINC | [6 years] |
| 2000 .05 | 2nd round-financing : 7.0 M€, by Technolife, ABN-Amro, Spef, and previous shareholders | RFINB | [3 years] |
| 1999 .09 | 1st round-financing : 1.5 M€, by 3i, Capricorn Venture, and a business angel | RFINA | [2 years] |
| 1997 .03 | Company founded by Dominique Costantini and Gilles Avenard | ORGF | [0 year] | Actualisation / Updating: 04-Janv-2010 |
|
